Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon

New Study Demonstrates Feasibility of Using RenalGuard-Guided Diuretic Therapy for Acute Heart Failure Patients

MILFORD, Mass. — May 29, 2018 — RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced new clinical study results demonstrating the feasibility of using RenalGuard®-Guided Diuretic Therapy to optimize fluid management in Acute Decompensated Heart Failure (ADHF) patients while alleviating related symptoms.

Social isolation in HF patients related to increased risk of death, use of healthcare resources

Patients with heart failure who describe themselves as being socially isolated have an increased risk of death and also have an increased use of healthcare resources, according to new research published in the Journal of the American Heart Association on May 23.

Thumbnail

Class I recall issued for Abbott’s HeartMate 3 heart pump

The FDA has issued a Class I recall of the HeartMate 3 Left Ventricular Assist System (Abbott) because a malfunction in the device’s outflow graft assembly could lead to graft occlusion, possibly reducing or stopping blood flow.

Thumbnail

Machine learning algorithm predicts survival for heart transplant candidates

Researchers from the University of California Los Angeles (UCLA) have developed a new algorithm which better predicts pre- and post-heart transplant survival than existing methods.

Beta-blockers equally effective for blacks, whites with HFrEF

A study published May 8 in the Journal of the American Heart Association suggests black and white patients with heart failure with reduced ejection fraction (HFrEF) derive similar benefit from beta-blockers, despite conflicting previous reports.

Thumbnail

Excessive patient deaths spur investigation into Houston heart transplant center

Baylor St. Luke’s Medical Center in Houston continues to tout itself as one of the top heart transplant centers in the country, even as quality measures lag well behind national averages.

Thumbnail

His bundle pacing trumps right ventricular approach in single-center study

A His bundle pacing (HBP) strategy was associated with a significant reduction in hospitalizations for heart failure when compared to pacemaker implantation via the right ventricle, according to a study published online May 14 in the Journal of the American College of Cardiology.

Thumbnail

Cardiovascular mortality rates for IHD, CHF vary 'significantly' across VA hospitals

Risk-standardized cardiovascular mortality rates vary ‘substantially’ for ischemic heart disease (IHD) and chronic heart failure (CHF) across the Department of Veterans Affairs medical centers (VAMCs), according to a study published online May 16 in JAMA Cardiology.

Displaying 641 - 648 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.